Simulations Plus
42505 10th Street West, Lancaster, CA, 93534, United States
Overview
Simulations Plus is a developer of Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) and Physiologically-Based Pharmacokinetic (PBPK) modeling and simulation software for the pharmaceutical and biotechnology, generics, chemical, cosmetic, and food ingredient industries today. Our software allows pharmaceutical scientists to predict certain key potential endpoints and dynamics, in silico, thereby reducing research & development costs and helping clients make better projects decisions... sooner. Founded in 1996, Simulations Plus employs over 60 employees and is publicly-traded on the NASDAQ stock exchange (ticker symbol = SLP).Our headquarters are based in Lancaster, California, with our pharmacometrics consulting team located in Buffalo, New York. Trusted distributors handle sales and scientific support in Asian territories. 19 of the top 20 pharmaceutical companies, plus numerous mid- and small-sized companies and all major regulatory agencies, license our modeling & simulation technology.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 7
Sector focus
- Biotechnology
- Computer
- Data Mining
- Enterprise Software
- Information Technology
- Life Science
- Software
Investment portfolio
- Nurocor
Led · Equity · Jul 2025
Nurocor offers a cloud-based software platform designed to improve efficiency, reusability, governance, and automation for pharmaceutical companies during the clinical development phase. Its solution is intended to significantly accelerate the typical clinical trial lifecycle and reduce the overall cost of clinical development. Founded in 2017, Nurocor says it is entering its next stage of growth and expects to partner with strategic investors to expand its offerings. In 2024 Simulations Plus invested $1 million in Nurocor through its Corporate Development Initiative to support early-stage technology companies. Simulations Plus indicated the investment could enable clients to deploy complementary solutions in clinical trial design, protocol development, and site competency and compliance. The company’s CEO, Alex Lazar, described the investment as a vote of confidence and said Nurocor looks forward to partnering with Simulations Plus to realize efficiencies through optimization and automation of clinical trials.